Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by H. Salmen
Pcn133 - The Societal Impact of Obinutuzumab in the First Line Treatment of Patients With Follicular Lymphoma in Germany
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Management of Patients With Follicular Lymphoma Treated First Line With Obinutuzumab
Asia-Pacific Journal of Clinical Oncology
Medicine
Oncology
Recent Advances in the First-Line Treatment of Follicular Non-Hodgkin Lymphoma
F1000Research
Genetics
Molecular Biology
Pharmacology
Biochemistry
Microbiology
Immunology
Medicine
Toxicology
Pharmaceutics
Pcn83 - The Use of Obinutuzumab in Treatment of Refractory and Relapsing Follicular Lymphoma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn141 - Cost-Effectiveness Analysis of Obinutuzumab for the Treatment of Patients With Previously Untreated Advanced Follicular Lymphoma in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Ongoing Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Impact of Treatment in Long-Term Survival Patients With Follicular Lymphoma: A Spanish Lymphoma Oncology Group Registry
PLoS ONE
Multidisciplinary
M7‐FLIPI Is Not Prognostic in Follicular Lymphoma Patients With First‐line Rituximab Chemo‐free Therapy
British Journal of Haematology
Hematology
Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
The Impact of First Complete Remission by PET-CT and Time to Next Treatment on Survival of Follicular Lymphoma Patients
Clinical Hematology International